Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CONCETTA M FORCHETTI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1184656852
CMS profile
189389
Location
ELK GROVE VILLAGE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$16,660.79

32 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $9,431.48 7
Eisai Inc. $5,900.00 3
Lilly USA, LLC $1,329.31 22

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CONCETTA M FORCHETTI

NPI 1184656852 · CMS profile ID 189389

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

ELK GROVE VILLAGE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184656852?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CONCETTA M FORCHETTI, NPI 1184656852, CMS profile ID 189389. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184656852?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). CONCETTA M FORCHETTI, NPI 1184656852, CMS profile ID 189389. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184656852?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
CONCETTA M FORCHETTI, NPI 1184656852, CMS profile ID 189389, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1184656852?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

32 matching records · $16,660.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 32 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–32 of 32.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $60.0010/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031316807 CMS
Eli Lilly and Company $20.0010/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031316809 CMS
Eli Lilly and Company $227.3410/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031325593 CMS
Eli Lilly and Company $4.6910/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031332675 CMS
Eli Lilly and Company $37.8010/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031430367 CMS
Eli Lilly and Company $8,750.0009/15/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031320799 CMS
Eli Lilly and Company $331.6509/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031443195 CMS
Lilly USA, LLC $189.0009/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031320801 CMS
Lilly USA, LLC $58.7409/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031325595 CMS
Lilly USA, LLC $26.4309/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031325597 CMS
Lilly USA, LLC $128.6209/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031325599 CMS
Lilly USA, LLC $54.0909/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031332677 CMS
Lilly USA, LLC $12.7509/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031332679 CMS
Lilly USA, LLC $189.0009/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031332681 CMS
Lilly USA, LLC $34.2609/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031332683 CMS
Lilly USA, LLC $12.7509/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031338837 CMS
Lilly USA, LLC $10.9809/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031338839 CMS
Lilly USA, LLC $24.0409/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031344329 CMS
Lilly USA, LLC $15.1209/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031344333 CMS
Lilly USA, LLC $0.9409/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031344337 CMS
Lilly USA, LLC $15.1209/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031344339 CMS
Lilly USA, LLC $0.9409/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031344343 CMS
Lilly USA, LLC $24.3809/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031344347 CMS
Lilly USA, LLC $51.6809/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031430371 CMS
Lilly USA, LLC $52.8809/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031443561 CMS
Lilly USA, LLC $206.5509/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031443565 CMS
Lilly USA, LLC $99.8709/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031443567 CMS
Lilly USA, LLC $51.3805/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031338841 CMS
Eisai Inc. $2,160.0005/17/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023305951 CMS
Eisai Inc. $2,700.0005/10/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023305949 CMS
Eisai Inc. $1,040.0003/09/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023305947 CMS
Lilly USA, LLC $69.7902/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031443571 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,113.42 4
PY2020 $565.00 1
PY2021 $38,624.37 33
PY2022 $15,350.00 6
PY2023 $16,660.79 32
PY2024 $39,378.02 40
PY2025 $50,287.88 49

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $908,463.90 81
PY2024 Principal investigator $630,831.36 79
PY2023 Recipient $591.95 2
PY2023 Principal investigator $1,785,779.63 92
PY2022 Recipient $10,066.00 2
PY2022 Principal investigator $1,648,640.76 51
PY2021 Recipient $1,310.44 2
PY2021 Principal investigator $1,377,364.84 65
PY2020 Recipient $2,195.35 2
PY2020 Principal investigator $1,008,121.30 81
PY2019 Recipient $294.51 1
PY2019 Principal investigator $1,007,212.44 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

34 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $2,019.00 11/25/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PRODROMAL TO MILD AD No dispute reported 06/30/2026 681100857
Principal investigator 1 Genentech, Inc. $1,500.00 10/24/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PRODROMAL TO MILD AD No dispute reported 06/30/2026 681103145
Principal investigator 1 Genentech, Inc. $4,350.00 10/02/2019 Non-covered Recipient Entity
BONAVENTURE MEDICAL FOUNDATION ADMINISTRATION OFFICE
PRODROMAL TO MILD AD No dispute reported 06/30/2026 681109061
Principal investigator 1 Genentech, Inc. $5,626.00 07/08/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PRODROMAL TO MILD AD No dispute reported 06/30/2026 681071603
Principal investigator 1 Biogen, Inc. $1,200.15 07/01/2019 Non-covered Recipient Entity
Alexian Brothers Neurosciences Institute
Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD) No dispute reported 06/30/2026 675310417
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $340.40 07/01/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD No dispute reported 06/30/2026 686166299
Principal investigator 1 Genentech, Inc. $837.00 05/23/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PRODROMAL TO MILD AD No dispute reported 06/30/2026 681085631
Principal investigator 1 Eli Lilly and Company $1,000.00 05/13/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
A RANDOMIZED, DOUBLE-BLIND, DELAYED-START STUDY OF LY3314814 AZD3293 IN EARLY ALZHEIMER'S DISEASE DEMENTIA EXTENSION OF STUDY AZES, THE AMARANTH STUDY No dispute reported 06/30/2026 654287099
Principal investigator 1 Merck Sharp & Dohme Corporation $1,500.00 03/13/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS MEDICAL CENTER
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 SCH 900931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease Prodromal AD. No dispute reported 06/30/2026 691311991
Principal investigator 1 Eisai Inc. $1,321.84 03/12/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544627
Principal investigator 1 Eisai Inc. $19,078.62 03/12/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544629
Principal investigator 1 Eisai Inc. $132.18 03/12/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544631
Recipient Eli Lilly and Company $294.51 03/12/2019 Covered Recipient Physician ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 654281927
Principal investigator 1 Genentech, Inc. $6,707.00 03/08/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PRODROMAL TO MILD AD No dispute reported 06/30/2026 681094441
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $966.17 03/07/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD No dispute reported 06/30/2026 686167861
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $73.82 02/19/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD No dispute reported 06/30/2026 686167851
Principal investigator 1 Eli Lilly and Company $825.00 02/15/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS MEDICAL CENTER - NEUROSCIENCE RESEARCH INSTITUTE
ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 654287831
Principal investigator 1 Merck Sharp & Dohme Corporation $1,110.00 02/13/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS MEDICAL CENTER
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 SCH 900931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease Prodromal AD. No dispute reported 06/30/2026 691311751
Principal investigator 1 Genentech, Inc. $4,103.00 02/11/2019 Non-covered Recipient Entity
BONAVENTURE MEDICAL FOUNDATION ADMINISTRATION OFFICE
PRODROMAL TO MILD AD No dispute reported 06/30/2026 681089417
Principal investigator 1 Eli Lilly and Company $130,527.94 01/31/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY No dispute reported 06/30/2026 654288315
Principal investigator 1 Eli Lilly and Company $1,976.61 01/28/2019 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 654297547
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,400.00 01/28/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD No dispute reported 06/30/2026 686167859
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $596.45 01/24/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD No dispute reported 06/30/2026 686167857
Principal investigator 1 Biogen, Inc. $5,562.83 01/18/2019 Non-covered Recipient Entity
Alexian Brothers Medical Center
Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD) No dispute reported 06/30/2026 675308951
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $304.33 01/18/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD No dispute reported 06/30/2026 686167855
Principal investigator 1 Biogen, Inc. $8,402.00 01/16/2019 Non-covered Recipient Entity
Alexian Brothers Medical Center
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-A IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease No dispute reported 06/30/2026 675308953
Principal investigator 1 Eli Lilly and Company $75.00 01/15/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 654287767
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $304.33 01/11/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD No dispute reported 06/30/2026 686167853
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $650.00 01/07/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD No dispute reported 06/30/2026 686167849
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,012.00 01/04/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD No dispute reported 06/30/2026 686166297
Principal investigator 1 Merck Sharp & Dohme Corporation $2,500.00 01/03/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS MEDICAL CENTER
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 SCH 900931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease Prodromal AD. No dispute reported 06/30/2026 691304517
Principal investigator 1 Biogen, Inc. $429,182.79 01/02/2019 Non-covered Recipient Entity
Alexian Brothers Medical Center
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease No dispute reported 06/30/2026 675308947
Principal investigator 1 Eli Lilly and Company $105,653.70 01/02/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 654287661
Principal investigator 1 Novartis Pharmaceuticals Corporation $266,374.28 01/01/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HEART AND VASCULAR INSTITUTE
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY OF TWO DOSES OF CNP520 IN PARTICIPANTS AT RISK FOR THE ONSET OF CLINICAL SYMPTOMS OF AD No dispute reported 06/30/2026 640709711